Symbols

Symbols

CARM

CARM

Carisma Therapeutics CSO Klichinsky Michael sells 56982 shares, buys 56982 at lower price.

Friday Oct 03, 2025

Carisma Therapeutics: CARM CSO Klichinsky sells shares at $0.25-$0.26.

Thursday Sep 18, 2025

Ocugen Terminates Merger Agreement with Carisma on September 16.

Carisma Therapeutics & Moderna Amend Collaboration, License Agreement for Cancer Treatments

Tuesday Sep 02, 2025

Carisma Therapeutics shares surge 121.39% intraday after announcing business merger with OrthoCellix.

Carisma Therapeutics Soars 133% on $5 Million Investment, Ocugen Merger

Friday Aug 08, 2025

CARISMA Therapeutics: D. Boral Capital maintains Buy, PT raised to $1 from $0.90

Saturday Aug 02, 2025

Ocugen Advances Gene Therapy for Blindness with Strategic Deals and Clinical Progress

Ocugen Q2 Revenue Surpasses Expectations, Advances Gene Therapy Trials

Friday Aug 01, 2025

Ocugen's 2026 Commercialization Plans and Gene Therapy Trials Advancements

Ocugen Initiates Dosing in GARDian3 Trial, Signs $11mln Korea Deal.

Ocugen Q2 results: dosing in Phase 2/3 trial, $11mln Korean rights deal.

Thursday Jul 24, 2025

KARO Reports 61% YoY Revenue Growth in Q1 FY26

Wednesday Jul 23, 2025

Carmila Reports Strong Q2 2025 Earnings, Raises 2025 Outlook

Wednesday Jul 16, 2025

Investigation into NVEE, CARM, and HLGN Shareholder Rights

Investors Investigate NV5, Carisma, and Heliogen Mergers and Sales.

Monday Jul 14, 2025

Investigation into proposed mergers and sales for shareholders of TURN, HLGN, CARM, and GNTY.

Saturday Jul 05, 2025

Investor Rights Law Firm Investigates Couchbase, Carisma, Enzo Biochem Merger Deals.

Wednesday Jul 02, 2025

Carisma Therapeutics shares fall 4.76% after-hours following merger announcement with OrthoCellix.

Friday Jun 27, 2025

Brodsky & Smith investigates Carisma Therapeutics' board for fiduciary breach.